COMPASS Pathways (CMPS) Stock Forecast & Price Target

Compare

1,950 Followers

See the Price Targets and Ratings of:

All Analysts

Top Analysts

Premium

CMPS Analyst Ratings

Strong Buy

10 Buy

0 Hold

0 Sell

Based on 10 analysts giving stock ratings to

COMPASS

Pathways

in the past 3 months

TipRanks enables you to focus on the analyst rating consensus of all analysts or only the top performers in the past 3 months

CMPS Stock 12 Month Forecast

Average Price Target

$16.80

▲(506.50%Upside)

Based on 10 Wall Street analysts offering 12 month price targets for COMPASS Pathways in the last 3 months. The average price target is $16.80 with a high forecast of $45.00 and a low forecast of $7.00. The average price target represents a 506.50% change from the last price of $2.77.

{"navigator":{"disabled":true},"exporting":{"enabled":false},"title":{"text":null},"chart":{"height":200,"style":{"fontFamily":"Roboto Flex","fontWeight":"400","color":"#5d5d5e"},"spacingTop":30,"spacingRight":60,"events":null},"yAxis":{"labels":{"style":{"color":"inherit"},"distance":6,"x":-6,"y":-6,"zIndex":1,"map_label_formatter":{"1":"$1","46":"$46","12.25":"$12.25","23.5":"$23.5","34.75":"$34.8"}},"plotLines":[{"color":"rgba(0,0,0,0)","value":45,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":-10,"text":"<div  class=\"positionrelative hoverZ3 triangleleft-bottom flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#199ca5\">High </span>\n\n  <span style=\"color:#199ca5\">$45.00</span>\n  </div></div>","useHTML":true}},{"color":"rgba(0,0,0,0)","value":16.8,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":0,"text":"<div  class=\"positionrelative hoverZ3 triangleleft flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#828080\">Average </span>\n\n  <span style=\"color:#828080\">$16.80</span>\n  </div></div>","useHTML":true}},{"color":"rgba(0,0,0,0)","value":7,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":10,"text":"<div  class=\"positionrelative hoverZ3 triangleleft-top flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#912767\">Low </span>\n\n  <span style=\"color:#912767\">$7.00</span>\n  </div></div>","useHTML":true}}],"tickPositions":[1,12.25,23.5,34.75,46],"lineColor":"#dddddd","gridLineWidth":1,"gridLineColor":"#dddddd","lineWidth":1,"title":{"text":""}},"plotOptions":{"series":{"states":{"inactive":{"opacity":1}}},"line":{"animation":{"duration":0},"dataLabels":{"allowOverlap":true},"borderWidth":1,"marker":{"enabled":true,"fillColor":"#FFFFFF","radius":3,"lineWidth":2,"symbol":"circle","lineColor":"#828080"}}},"xAxis":{"labels":{"style":{"color":"inherit"},"rotation":0,"map_label_formatter":{"3":"Aug<br/>2024","6":"Nov<br/>2024","9":"Mar<br/>2025","12":"Jun<br/>2025","25":"Jun<br/>2026"}},"tickPositions":[3,6,9,12,25],"plotLines":[{"color":"#dddddd","width":1,"value":12},{"color":"#dddddd","width":1,"value":12}],"lineWidth":0,"gridLineWidth":1,"gridLineColor":"#dddddd","tickLength":0},"legend":{"symbolRadius":0,"symbolPadding":4,"symbolHeight":14,"borderWidth":0,"symbolWidth":14,"align":"left","verticalAlign":"bottom","enabled":false},"tooltip":{"backgroundColor":"rgba(0,0,0,0)","useHTML":true,"borderWidth":0,"borderColor":"rgba(0,0,0,0)","padding":0,"shadow":null,"headerFormat":"","footerFormat":"","pointFormat":"<div class=\"flexccc lineHeight2 bgwhite shadow2 px3 py3 radiismall fonth10_semibold\">\n                <span class=\"colorgray-3 mb4\">{point.date:%b %d ,%Y}</span>\n                <span>Analyst Consensus</span>\n                {point.info}\n          </div>\n           </div>"},"credits":{"enabled":false},"accessibility":{"description":""},"responsive":{"rules":[{"chartOptions":{"chart":{"spacing":[0,0,0,0],"margin":[30,60,40,5]},"xAxis":{"tickPositions":[3,12,25.25]},"yAxis":{"labels":{"enabled":false}},"title":{"text":null},"subtitle":{"text":null}},"condition":{"maxWidth":500}}]},"series":[{"lineWidth":2,"dashStyle":"ShortDash","name":"High","type":"line","color":"#199ca5","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,4.37,7.495384615384616,10.62076923076923,13.746153846153849,16.871538461538464,19.99692307692308,23.122307692307697,26.24769230769231,29.373076923076926,32.49846153846154,35.62384615384615,38.74923076923077,41.87461538461539,{"y":45,"marker":{"fillColor":"#199ca5","lineColor":"#199ca5","enabled":true,"symbol":"circle"}}]},{"lineWidth":2,"dashStyle":"ShortDash","name":"Average","type":"line","color":"#828080","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,4.37,5.326153846153846,6.282307692307692,7.2384615384615385,8.194615384615386,9.150769230769232,10.106923076923078,11.063076923076924,12.01923076923077,12.975384615384616,13.931538461538462,14.887692307692308,15.843846153846155,{"y":16.8,"marker":{"fillColor":"#828080","lineColor":"#828080","enabled":true,"symbol":"circle"}}]},{"lineWidth":2,"dashStyle":"ShortDash","name":"Low","type":"line","color":"#912767","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,4.37,4.572307692307692,4.774615384615385,4.976923076923077,5.179230769230769,5.381538461538462,5.583846153846154,5.786153846153846,5.9884615384615385,6.190769230769231,6.393076923076923,6.595384615384615,6.797692307692308,{"y":7,"marker":{"fillColor":"#912767","lineColor":"#912767","enabled":true,"symbol":"circle"}}]},{"type":"line","data":[{"y":8.48,"date":1714521600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 11,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":7.38,"date":1717200000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 8,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":5.95,"date":1719792000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 8,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":6.88,"date":1722470400000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 13,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":7.48,"date":1725148800000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 12,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":5.96,"date":1727740800000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 13,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":4.75,"date":1730419200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 10,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":3.78,"date":1735689600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 12,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":4.31,"date":1738368000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 16,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":3.93,"date":1740787200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 12,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":2.79,"date":1743465600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 11,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":4.1,"date":1746057600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 12,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":4.37,"date":1748736000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 16,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"fillColor":"black","lineColor":"black","enabled":true,"symbol":"circle"}},null,null,null,null,null,null,null,null,null,null,null,null],"color":"#0666a7"}]}

Highest Price Target$45.00

Average Price Target$16.80

Lowest Price Target$7.00

The highest, average, and lowest price target of all analysts. Click on ‘Top Analysts’ to focus on the best performers.

Detailed List of Analyst Forecasts

Michael OkunewitchMaxim Group

Maxim Group

$12

Buy

333.21%

Upside

Reiterated

06/26/25

Analysts Offer Insights on Healthcare Companies: Medtronic (NYSE: MDT) and COMPASS Pathways (NASDAQ: CMPS)

Thomas ShraderBTIG

BTIG

$12→$7

Buy

152.71%

Upside

Reiterated

06/24/25

Compass Pathways price target lowered to $7 from $12 at BTIGCompass Pathways price target lowered to $7 from $12 at BTIG

Gavin Clark-GartnerEvercore ISI

Evercore ISI

$11

Buy

297.11%

Upside

Reiterated

06/23/25

Analysts Offer Insights on Healthcare Companies: COMPASS Pathways (NASDAQ: CMPS), Evolent Health (NYSE: EVH) and Tandem Diabetes Care (NASDAQ: TNDM)

Paul MatteisStifel Nicolaus

Stifel Nicolaus

$11

Buy

297.11%

Upside

Reiterated

06/23/25

Compass Pathways weakness 'significantly overdone,' says StifelCompass Pathways weakness 'significantly overdone,' says Stifel

Sumant KulkarniCanaccord Genuity

Canaccord Genuity

$15

Buy

441.52%

Upside

Reiterated

06/23/25

Compass Pathways weakness a buying opportunity, says CanaccordCompass Pathways weakness a buying opportunity, says Canaccord

Patrick TrucchioH.C. Wainwright

H.C. Wainwright

$45

Buy

1524.55%

Upside

Reiterated

06/23/25

Compass Pathways results 'historic first' for psychedelics, says H.C. WainwrightCompass Pathways results 'historic first' for psychedelics, says H.C. Wainwright

Joshua SchimmerCantor Fitzgerald

Cantor Fitzgerald

$12

Buy

333.21%

Upside

Initiated

05/27/25

Cantor Fitzgerald Reaffirms Their Buy Rating on COMPASS Pathways (CMPS)

Ritu BaralTD Cowen

TD Cowen

$23

Buy

730.32%

Upside

Reiterated

05/27/25

TD Cowen Sticks to Its Buy Rating for COMPASS Pathways (CMPS)

Vikram PurohitMorgan Stanley

Morgan Stanley

$17

Buy

513.72%

Upside

Reiterated

05/15/25

Positive Outlook for COMPASS Pathways Amid Promising Clinical Developments and Strong Financial Position

Leonid TimashevRBC Capital

RBC Capital

$15

Buy

441.52%

Upside

Reiterated

05/08/25

Analysts Offer Insights on Healthcare Companies: COMPASS Pathways (NASDAQ: CMPS) and GH Research (NASDAQ: GHRS)

Elemer PirosLucid Capital

Lucid Capital

$30→$9

Buy

224.91%

Upside

Reiterated

01/27/25

Compass Pathways (CMPS) PT Lowered to $9 at Rodman RenshawRodman Renshaw analyst Elemer Piros lowered the price target on Compass Pathways (NASDAQ: CMPS) to $9.00 (from $30.00) while maintaining a Buy rating.

Francois BriseboisOppenheimer

Oppenheimer

$25

Buy

802.53%

Upside

Reiterated

08/02/24

Oppenheimer Sticks to Their Buy Rating for COMPASS Pathways (CMPS)

Ranks

Any

Analyst Rating

Any

Upside/ Downside

Any

Action

Any

Michael OkunewitchMaxim Group

Maxim Group

$12

Buy

333.21%

Upside

Reiterated

06/26/25

Analysts Offer Insights on Healthcare Companies: Medtronic (NYSE: MDT) and COMPASS Pathways (NASDAQ: CMPS)

Thomas ShraderBTIG

BTIG

$12→$7

Buy

152.71%

Upside

Reiterated

06/24/25

Compass Pathways price target lowered to $7 from $12 at BTIGCompass Pathways price target lowered to $7 from $12 at BTIG

Gavin Clark-GartnerEvercore ISI

Evercore ISI

$11

Buy

297.11%

Upside

Reiterated

06/23/25

Analysts Offer Insights on Healthcare Companies: COMPASS Pathways (NASDAQ: CMPS), Evolent Health (NYSE: EVH) and Tandem Diabetes Care (NASDAQ: TNDM)

Paul MatteisStifel Nicolaus

Stifel Nicolaus

$11

Buy

297.11%

Upside

Reiterated

06/23/25

Compass Pathways weakness 'significantly overdone,' says StifelCompass Pathways weakness 'significantly overdone,' says Stifel

Sumant KulkarniCanaccord Genuity

Canaccord Genuity

$15

Buy

441.52%

Upside

Reiterated

06/23/25

Compass Pathways weakness a buying opportunity, says CanaccordCompass Pathways weakness a buying opportunity, says Canaccord

Patrick TrucchioH.C. Wainwright

H.C. Wainwright

$45

Buy

1524.55%

Upside

Reiterated

06/23/25

Compass Pathways results 'historic first' for psychedelics, says H.C. WainwrightCompass Pathways results 'historic first' for psychedelics, says H.C. Wainwright

Joshua SchimmerCantor Fitzgerald

Cantor Fitzgerald

$12

Buy

333.21%

Upside

Initiated

05/27/25

Cantor Fitzgerald Reaffirms Their Buy Rating on COMPASS Pathways (CMPS)

Ritu BaralTD Cowen

TD Cowen

$23

Buy

730.32%

Upside

Reiterated

05/27/25

TD Cowen Sticks to Its Buy Rating for COMPASS Pathways (CMPS)

Vikram PurohitMorgan Stanley

Morgan Stanley

$17

Buy

513.72%

Upside

Reiterated

05/15/25

Positive Outlook for COMPASS Pathways Amid Promising Clinical Developments and Strong Financial Position

Leonid TimashevRBC Capital

RBC Capital

$15

Buy

441.52%

Upside

Reiterated

05/08/25

Analysts Offer Insights on Healthcare Companies: COMPASS Pathways (NASDAQ: CMPS) and GH Research (NASDAQ: GHRS)

Elemer PirosLucid Capital

Lucid Capital

$30→$9

Buy

224.91%

Upside

Reiterated

01/27/25

Francois BriseboisOppenheimer

Oppenheimer

$25

Buy

802.53%

Upside

Reiterated

08/02/24

Oppenheimer Sticks to Their Buy Rating for COMPASS Pathways (CMPS)

Stocks with the Highest Top Analyst Consensus in the Healthcare Sector

xxx

Find stocks in the Healthcare sector that are highly recommended by Top Performing Analysts.

Best Analysts Covering COMPASS Pathways

1 Month

xxx

Success Rate

7/16 ratings generated profit

Average Return

-1.65%

reiterated a xxx

rating 7 days ago

Copying xxxxxxxxxxxxxxxxxx

trades and holding each position for 1 Month would result in 43.75% of your transactions generating a profit, with an average return of -1.65% per trade.

3 Months

xxx

Success Rate

10/23 ratings generated profit

Average Return

-5.67%

reiterated a xxx

rating 7 days ago

Copying xxxxxxxxxxxxxxxxxx

trades and holding each position for 3 Months would result in 43.48% of your transactions generating a profit, with an average return of -5.67% per trade.

1 Year

Elemer PirosLucid Capital

Success Rate

1/11 ratings generated profit

Average Return

-36.85%

reiterated a buy rating 5 months ago

Copying Elemer Piros's trades and holding each position for 1 Year would result in 9.09% of your transactions generating a profit, with an average return of -36.85% per trade.

2 Years

xxx

Success Rate

1/16 ratings generated profit

Average Return

-57.21%

reiterated a xxx

rating 7 days ago

Copying xxxxxxxxxxxxxxxxxx

trades and holding each position for 2 Years would result in 6.25% of your transactions generating a profit, with an average return of -57.21% per trade.

The Best Analyst Covering tool allows you to follow the analysts who have the best success rates and average returns on a specific stock. Only analysts that gave a Buy or Sell rating on the stock in the past 12 months are eligible for inclusion in this tool. Follow the analysts of your choice to receive real-time updates when they publish a new rating.

CMPS Analyst Recommendation Trends

Rating

Feb 25

Mar 25

Apr 25

May 25

Jun 25

Strong Buy

Buy

Hold

Sell

Strong Sell

total

In the current month, CMPS has received 16 Buy Ratings, 0 Hold Ratings, and 0 Sell Ratings. CMPS average Analyst price target in the past 3 months is 16.80.

Each month's total comprises the sum of three months' worth of ratings.

CMPS Financial Forecast

CMPS Earnings Forecast

Next quarter’s earnings estimate for CMPS is -$0.43 with a range of -$0.56 to -$0.34. The previous quarter’s EPS was -$0.24. CMPS beat its EPS estimate 50.00% of the time in the past 12 months, while its overall industry beat the EPS estimate 58.16% of the time in the same period. In the last calendar year CMPS has Outperformed its overall industry.

No data currently available

CMPS Sales Forecast

Next quarter’s sales forecast for CMPS is $0.00 with a range of $0.00 to $0.00. The previous quarter’s sales results were $0.00. CMPS beat its sales estimates 0.00% of the time in past 12 months, while its overall industry beat sales estimates 47.46% of the time in the same period. In the last calendar year CMPS has Preformed in-line its overall industry.

CMPS Stock Forecast FAQ

What is CMPS’s average 12-month price target, according to analysts?

Based on analyst ratings, COMPASS Pathways’s 12-month average price target is 16.80.

What is CMPS’s upside potential, based on the analysts’ average price target?

COMPASS Pathways has 506.50% upside potential, based on the analysts’ average price target.

Can I see which stocks the top-ranking analysts are rating?

Yes, go to the Analysts’ Top Stocks tool to see stocks with a Strong Buy or Strong Sell analyst rating consensus, according to the top performers.

How can I follow the stock ratings of top Wall Street analysts?

Head over to our Expert Center to see a list of the top 100 Wall Street analysts and follow the analysts of your choice. Visit their profiles for more details about their stock ratings and see how they perform on a stock-by-stock basis.

Is CMPS a Buy, Sell or Hold?

COMPASS Pathways has a consensus rating of Strong Buy which is based on 10 buy ratings, 0 hold ratings and 0 sell ratings.

What is COMPASS Pathways’s price target?

The average price target for COMPASS Pathways is 16.80. This is based on 10 Wall Streets Analysts 12-month price targets, issued in the past 3 months.
The highest analyst price target is $45.00 ,the lowest forecast is $7.00. The average price target represents 506.50% Increase from the current price of $2.77.

What do analysts say about COMPASS Pathways?

COMPASS Pathways’s analyst rating consensus is a Strong Buy. This is based on the ratings of 10 Wall Streets Analysts.

How can I buy shares of CMPS?

Open a brokerage account, see exclusive account opening deals on our Best Online Brokers page.

Become an Expert with TipRanks Premium

What am I Missing?

Make informed decisions based on Top Analysts' activity

Know what industry insiders are buying

Get actionable alerts from top Wall Street Analysts

Find out before anyone else which stock is going to shoot up

Get powerful stock screeners & detailed portfolio analysis

Subscribe Now See Plans & Pricing

COMPASS Pathways (CMPS) Stock Forecast & Price Target

CMPS Analyst Ratings

CMPS Stock 12 Month Forecast

Average Price Target

Detailed List of Analyst Forecasts​

Best Analysts Covering COMPASS Pathways

CMPS Analyst Recommendation Trends

CMPS Financial Forecast

CMPS Earnings Forecast

CMPS Sales Forecast

CMPS Stock Forecast FAQ

Become an Expert with TipRanks Premium

Detailed List of Analyst Forecasts